Published Research and Presentations Publications Presentations Publications Presentations Abstract 325: UNISON – nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy. UNISoN ASCO GU 2021 - Virtual Meeting 11/02/2021 Craig Gedye, FRACP, MBChB, PhD Abstract TPS177: ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901) ENZA-p ASCO GU 2021 - Virtual Meeting 11/02/2021 Louise Emmett, FRACP, MBChB, MD Abstract TPS390: P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs). P3BEP ASCO GU 2021 - Virtual Meeting 11/02/2021 Shalini Subramaniam, MBBS Abstract TPS367: Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP 1601). KEYPAD ASCO GU 2021 - Virtual Meeting 11/02/2021 Craig Gedye, PhD, FRACP Abstract 6: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603). TheraP ASCO GU 2021 - Virtual Meeting 11/02/2021 Michael S Hofman, FRACP, MBBS TheraP: A randomised phase 2 trial of Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel – initial results (ANZUP protocol 1603) TheraP ASCO 2020 - Virtual Meeting 29/05/2020 Hofman, M et al. Abstract TPS768: UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma. UNISoN ASCO GU 2020 13/02/2020 Craig Gedye, PhD, FRACP Abstract TPS602: Adding mitomycin to Bacillus Calmette-Guérin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301) BCG+MM ASCO GU 2020 13/02/2020 Elizabeth Liow, MBBS, FRACP Abstract TPS425: P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs) P3BEP ASCO GU 2020 13/02/2020 Shalini Subramaniam, MBBS Abstract 485: Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502) PCR MIB ASCO GU 13-15 February 2020 13/02/2020 Andrew Weickhardt, FRACP, MBBS Load More
Abstract 325: UNISON – nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy. UNISoN ASCO GU 2021 - Virtual Meeting 11/02/2021 Craig Gedye, FRACP, MBChB, PhD
Abstract TPS177: ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901) ENZA-p ASCO GU 2021 - Virtual Meeting 11/02/2021 Louise Emmett, FRACP, MBChB, MD
Abstract TPS390: P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs). P3BEP ASCO GU 2021 - Virtual Meeting 11/02/2021 Shalini Subramaniam, MBBS
Abstract TPS367: Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP 1601). KEYPAD ASCO GU 2021 - Virtual Meeting 11/02/2021 Craig Gedye, PhD, FRACP
Abstract 6: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603). TheraP ASCO GU 2021 - Virtual Meeting 11/02/2021 Michael S Hofman, FRACP, MBBS
TheraP: A randomised phase 2 trial of Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel – initial results (ANZUP protocol 1603) TheraP ASCO 2020 - Virtual Meeting 29/05/2020 Hofman, M et al.
Abstract TPS768: UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma. UNISoN ASCO GU 2020 13/02/2020 Craig Gedye, PhD, FRACP
Abstract TPS602: Adding mitomycin to Bacillus Calmette-Guérin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301) BCG+MM ASCO GU 2020 13/02/2020 Elizabeth Liow, MBBS, FRACP
Abstract TPS425: P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs) P3BEP ASCO GU 2020 13/02/2020 Shalini Subramaniam, MBBS
Abstract 485: Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502) PCR MIB ASCO GU 13-15 February 2020 13/02/2020 Andrew Weickhardt, FRACP, MBBS
